19,060 Shares in Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP) Bought by Victory Capital Management Inc.

Victory Capital Management Inc. bought a new position in shares of Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP) during the 2nd quarter, according to the company in its most recent disclosure with the SEC. The fund bought 19,060 shares of the biopharmaceutical company’s stock, valued at approximately $862,000. Victory Capital Management Inc. owned about 0.18% of Corbus Pharmaceuticals as of its most recent SEC filing.

Several other institutional investors and hedge funds also recently added to or reduced their stakes in CRBP. Rhumbline Advisers acquired a new stake in Corbus Pharmaceuticals during the 2nd quarter worth $638,000. Mirae Asset Global Investments Co. Ltd. acquired a new stake in Corbus Pharmaceuticals during the 1st quarter worth $976,000. Bank of New York Mellon Corp acquired a new stake in Corbus Pharmaceuticals during the 2nd quarter worth $1,368,000. TD Asset Management Inc boosted its stake in Corbus Pharmaceuticals by 92.5% during the 2nd quarter. TD Asset Management Inc now owns 40,800 shares of the biopharmaceutical company’s stock worth $1,846,000 after purchasing an additional 19,600 shares during the last quarter. Finally, Altitude Crest Partners Inc. acquired a new stake in Corbus Pharmaceuticals during the 1st quarter worth $4,069,000. Institutional investors and hedge funds own 64.64% of the company’s stock.

Corbus Pharmaceuticals Price Performance

NASDAQ CRBP opened at $19.51 on Friday. The firm’s 50-day moving average is $55.03 and its two-hundred day moving average is $46.93. Corbus Pharmaceuticals Holdings, Inc. has a 12 month low of $3.03 and a 12 month high of $61.90. The stock has a market capitalization of $208.50 million, a P/E ratio of -2.80 and a beta of 2.56.

Corbus Pharmaceuticals (NASDAQ:CRBP) last posted its earnings results on Tuesday, August 6th. The biopharmaceutical company reported ($0.90) EPS for the quarter, beating analysts’ consensus estimates of ($1.19) by $0.29. As a group, analysts anticipate that Corbus Pharmaceuticals Holdings, Inc. will post -3.77 EPS for the current year.

Analyst Upgrades and Downgrades

Several brokerages have issued reports on CRBP. HC Wainwright reaffirmed a “buy” rating and set a $80.00 target price on shares of Corbus Pharmaceuticals in a research note on Tuesday, August 6th. Wedbush lowered their price target on shares of Corbus Pharmaceuticals from $85.00 to $51.00 and set an “outperform” rating on the stock in a research report on Friday. Lifesci Capital raised shares of Corbus Pharmaceuticals to a “strong-buy” rating in a research report on Wednesday, August 21st. StockNews.com cut shares of Corbus Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Saturday, August 10th. Finally, Oppenheimer boosted their price target on shares of Corbus Pharmaceuticals from $80.00 to $88.00 and gave the company an “outperform” rating in a research report on Wednesday, August 7th. One equities research analyst has rated the stock with a sell rating, seven have given a buy rating and one has given a strong buy rating to the company’s stock. Based on data from MarketBeat, Corbus Pharmaceuticals presently has an average rating of “Moderate Buy” and a consensus target price of $65.86.

About Corbus Pharmaceuticals

Corbus Pharmaceuticals Holdings, Inc, a biopharmaceutical company, develops products to defeat serious illness. It develops CRB-701, an antibody drug conjugate (ADC) that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload of monomethyl auristatin E (MMAE), which is in Phase I clinical trial; CRB-601, an anti-integrin monoclonal antibody that blocks the activation of TGFß expressed on cancer cells for the treatment of solid tumors; CRB-913, a peripherally restricted cannabinoid type-1 (CB1) receptor inverse agonist for the treatment of obesity.